Oncotelic Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Oncotelic Therapeutics generated cash of -$1,321,047, which is more than the previous year. Cash used in financing activities reached the amount of $1,250,000 last year. Net change in cash is therefore -$71,047.
Cash Flow
| 2014 | -12.15M | -17K | 35.19M |
|---|---|---|---|
| 2015 | -11.92M | -13K | 9.19M |
| 2016 | -15.23M | -8.51M | 0 |
| 2017 | -10.93M | 8.51M | 1.41M |
| 2018 | -2.84M | 0 | 2.35M |
| 2019 | -2.28M | 189.28K | 2.17M |
| 2020 | -2.81M | 0 | 3.22M |
| 2021 | -4.43M | 0 | 4.52M |
| 2022 | -1.45M | 0 | 1.12M |
| 2023 | -1.32M | 0 | 1.25M |
OTLC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 261.45K | 588.76K | 494.01K | 81.96K | 2.49K | 1.11M | 3.53M | 27.28M | 30.03M | 7.00M |
Operating activities | ||||||||||
Net income | -7.90M | 4.67M | -10.51M | -9.97M | -6.63M | -2.73M | -13.81M | -13.65M | -13.65M | -12.64M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 12.84K | 61.51K | 364.21K | 60.65K | 2K | 9K | 19K | 20K | 109K |
Stock-based compensation expense | 0 | 902.14K | 763.31K | 2.14M | 340.67K | 0 | 835K | 804K | 806K | 414K |
| Deferred income tax benefit | 0 | 902.14K | 763.31K | 2.14M | 340.67K | 0 | 835K | 804K | 806K | 414K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -45.93K | 802.96K | 249.66K | 470.77K | 1.17M | -599K | 35K | 0 | 684K | 168K |
Cash generated by operating activities | -1.32M | -1.45M | -4.43M | -2.81M | -2.28M | -2.84M | -10.93M | -15.23M | -11.92M | -12.15M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -21.01M | 0 | 0 |
Investments In Property Plant And Equipment | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13K | -17K |
Acquisitions Net | 0 | 0 | 0 | 0 | 189.28K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 189.28K | 0 | 8.51M | -8.51M | -13K | -17K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 158.82K | 1.96M | 2.92M | 83K | 2.35M | 0 | 0 | 9.19M | 25.68M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -125K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.41M | 0 | -407.5K | -50K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.25M | 1.12M | 4.52M | 3.22M | 2.17M | 2.35M | 1.41M | 0 | 9.19M | 35.19M |
Net Change In Cash | -71.04K | -327.31K | 94.75K | 412.05K | 79.46K | -486K | -2.42M | -23.75M | -2.74M | 23.02M |
Cash at end of period | 190.40K | 261.45K | 588.76K | 494.01K | 81.96K | 629K | 1.11M | 3.53M | 27.28M | 30.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |